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Abstract 
Review on KITLG, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: MGF, SCF 
HGNC (Hugo): KITLG 
Location: 12q21.32 
DNA/RNA 
Description 
KITLG/SCF is encoded by 10 exons (transcript 
variant b) and 9 exons (transcript variant a). 
Transcription 
Transcript variant a: 5376 bp. The isoform a lacks 
the primary proteolytic cleavage site. As a result, 
the product encoded by this isoform is a membrane 
bound protein. 
Transcript variant b: 5460 bp. The transcript 
isoform b contains the primary proteolytic-cleavage 
site and encodes a soluble product. 
Although SCF exists as a monomer, Zhang et al. 
and Hsu et al. evidenced that dimerisation of SCF 
has been associated with KIT receptor activation 
and signal transduction. They demonstrated, 
through the crystal analysis, that the SCF dimer 
complex comprises of two SCF monomers with 
head-to-head interaction in order to form an 
elongated homo-dimer stabilised by both polar and 
non polar interactions. 
Alternative splicing of the SCF transcript results in 
the inclusion or exclusion of an exon 6 which 
contains a proteolytic cleavage site, recognised by 
metalloprotease-9 enzyme that cleaves after an 
alanine residue (Ala 189) in the extracellular 
region, producing the 165-aminoacid soluble SCF. 
There are other proteases that have been suggested 
to be responsible for cleavage of membrane-bound 
SCF, as chymase-1, ADAM17 and ADAM33. The 
splice form that lacks the cleavage site and remains 
linked to the cell surface is a result of the 
alternative splicing within exon 6 which skip the 
cleavage site for the metalloprotease-9. 
In total, there are six alternative transcripts of SCF 
in humans, out of which four encode protein 
(http://www.ensembl.org). 
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Protein 
Description 
The membrane bound form is a surface molecule of 
248 aa, that includes 23 aa of the highly 
hydrophobic transmembrane domain; the second 
form corresponds to a soluble protein constituted by 
the first 165 aa of the extracellular domain released 
by a posttranslational processing, consisting in a 
proteolytic cleavage of the mature SCF in the 
extracellular juxtamembrane region. The full length 
transcripts encode for a transmembrane precursor of 
the soluble protein; an alternative splicing that 
involves the region corresponding to exon 6 of the 
SCF cDNA, which contains the proteolytic 
cleavage site, encodes for a surface molecule. Jiang 
et al. evidenced the crystallized structure of 
interaction between SCF and c-KIT and revealed 
the common structure of a bundle of 4 α-helices 
linked by two intra-molecular disulfide bridges. 
Expression 
According to description of Bedell et al., the SCF 
encoding mRNA is characterized by a short 5' 
untranslated region, a 0.8 kb open reading frame, 
and by a long 3' untranslated region. In the 5' 
region, there are three ATG motifs where the last is 
used as the initiation site.  
A TATA box consensus sequence (TATAAA) and 
three overlapping GGCGGG motifs are located at 
twenty-eight bases upstream of the transcription 
initiation sites. These are binding sites for the 
transcription factors TFIID and SP1, respectively. 
Kobi et al. reported that the POU-homeodomain 
transcription factor POU3F2, expressed in neurons 
and in melanoma cells, regulates the SCF promoter 
through a cluster of four closely spaced binding 
sites located in the proximal promoter. It should be 
noted that UVB light is also known to induce 
expression of SCF in human epidermal cells both 
on the mRNA level and is soluble as well as 
membrane-bound SCF, but the mechanism of 
induction of SCF gene expression by UVB is still 
unknown.  
It has been also reported that HIF-1 upregulates the 
expression of SCF in response to hypoxia as well as 
to growth factor receptor activation.  
In Sertoli cells, SCF expression is up-regulated by 
treatment with follicle stimulating hormone (FSH) 
through an increasing of cAMP level. 
SCF transcripts have been found in the cells 
surrounding kit-positive cells, such as granulosa 
and Sertoli cells, bone marrow stromal cells and in 
fibroblasts, keratinocytes and mature granulocytes; 
SCF expression of peripheral lymphocytes and 
monocytes is still controversial. 
Localisation 
Plasma membrane or interstitial space.  
It is interesting to note that Faber et al. showed that 
disintegrin and metalloproteinase ADAM10 has an 
important role in mast cell migration and 
distribution. 
In fact, they evidenced that ADAM 10, expressed at 
high levels by mast cells, is required for SCF-
mediated mast cell migration. 
Function 
SCF/MGF binding of receptor KIT, with tyrosine 
kinase activity, induces receptor dimerization, 
autophosphorylation and signal transduction via 
molecules containing SH2-domains; the soluble and 
the transmembrane protein have a different 
biological activity; the soluble form mainly 
stimulates cellular proliferation; the membrane-
bound isoform induces an activation of the receptor 
more prolonged than the soluble one. 
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Homology 
With PDGFRb, PDGFRa, and CSF-1. 
Mutations 
Germinal 
Human mutations are yet unknown in human 
MGF/SCF gene; mouse mutations at the murine 
steel (Sl) locus that encodes MGF are known and 
give rise to deficiencies in pigment cells, germ 
cells, and blood cells; in particular the steel-Dickie 
(Sld) mouse has a 4.0-kb intragenic deletion that 
truncates the Sl coding sequence; Sld mice are only 
capable of encoding a soluble truncated growth 
factor that lacks both transmembrane and 
cytoplasmic domains. 
Implicated in 
Mastocytosis 
Note 
In skin from patients with mastocytosis, MGF was 
found prevalently free in the dermis and in 
extracellular spaces between keratinocytes 
suggesting the presence of a soluble form of the 
protein; altered distribution of mast cell growth 
factor in the skin of patients with cutaneous 
mastocytosis is consistent with abnormal 
production of the soluble form of the factor, 
resulting by an increased cleavage of SCF with 
excessive release of a soluble form from the 
normally membrane bound form; no sequence 
abnormalities were detected in MGF mRNA.  
Janson et al. evidenced that RIN3, a RAS effector, 
is highly enriched in mast cells, and that is involved 
in a complex with BIN2, a membrane binding 
protein implicated in endocytosis. They also 
demonstrated that RIN3 negatively regulates KIT 
internalization process and also that KIT down-
regulation is enhanced by RIN3 activity. 
Gynecological tumors 
Note 
Findings obtained on three cervical carcinomas 
(ovarian serous adenocarcinoma, small cell 
carcinoma and ovarian immature teratoma) and two 
gynecological cancer cell lines (ME180 and 
HGCM) demonstrate coexpression of c-Kit receptor 
and SCF; these observations are consistent with the 
possibility that an autocrine activation of SCF/KIT 
system might be involved in gynecological 
malignancies. 
Small cell lung cancer 
Note 
SCF is expressed in small cell lung cancer (SCLC); 
abundant expression of SCF and c-Kit mRNA was 
seen in 32% of SCLC cell lines and 66% of SCLC 
tumors; an autocrine mechanism in the 
pathogenesis of SCLC is strongly suggested. 
Prostate cancer 
Note 
Recently, Wiesner et al. suggested that SCF release 
from prostate cancer (PC) cells to the extracellular 
milieu has a potential contribution to prostate 
cancer bone metastasis. 
Pancreatic cancer 
Note 
c-KIT expression and SCF/c-KIT interaction are 
strictly linked to invasion and proliferation of 
pancreatic cancer cells. Zhang et al. recently 
showed the SCF/c-KIT signaling promotes the 
invasion of pancreatic cells, via HIF-1α in 
normoxic condition and through PI3K/AKT and 
RAS/MEK/ERK pathways. 
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